Sodium Glucose co-transporter – 2 (SGLT-2) inhibitors are class of oral antidiabetic drugs used in the treatment of Type II diabetes Mellitus. They act on the SGLT- 2 protein expressed in the renal proximal convoluted tubules to reduce the absorption of filtered glucose, decrease the renal threshold of glucose and promote glucose excretion. They have gained popularity due to their beneficial effects on heart and kidneys. However their use is associated with increased risk of Euglycemic ketoacidosis. Here we present a case where SGLT – 2 inhibitor used in combination with Insulin in a patient of LADA was associated with D.K.A where severe Metabolic acidosis persisted even after correction of hyperglycemia and dehydration which did not respond to continuous infusion of Dextrose, insulin and Sodium bicarbonate, ultimately requiring Hemodialysis.